Cancer Clinical Pharmacology
Edited by Jan H. M. Schellens, Howard L. McLeod, and David R. Newell
Author Information
Edited by Jan H. M. Schellens, Consultant Medical Oncologist and Clinical Pharmacologist, The Netherlands Cancer Institute, Amsterdam and the Faculty of Pharmaceutical Sciences, Division of Drug Toxicology, University of Utrecht, The Netherlands, Howard L. McLeod, Associate Professor, Washington University School of Medicine, St. Louis, USA, and David R. Newell, Professor of Cancer Therapeutics and Scientific Director, Northern Institute for Cancer Research, University of Newcastle, UK
Contributors:
Sharyn D. Baker, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA; Jos H. Beijnen, Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands; Alan V. Boddy, Northern Institute for Cancer Research, University of Newcastle, UK; Jim Cassidy, Institute of Medical Sciences, University of Aberdeen, UK; Etienne Chatelut, Institute Claudius Regaud, Cancer Center Toulouse, France; Luca Gianni, Division of Medical Oncology A, Instituto Nazionale Tumori, Milan, Italy; D. Paul Harkin, Department of Oncology, The Queen's University of Belfast, Belfast City Hospital, Northern Ireland; Steven W. Johnson, University of Pennsylvania Cancer Center, Philadelphia, USA; Patrick G. Johnston, Department of Oncology, The Queen's University of Belfast, Belfast City Hospital, Northern Ireland; Wandena S. Lakhai, Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands; Jan Liliemark, Department of Experimental Haematology, Karolinska Institute, Stockholm, Sweden; Alberta Locatelli, Division of Medical Oncology A, Instituto Nazionale Tumori, Milan, Italy; Per E. Lonning, Department of Oncology, University of Bergen, Haukeland University Hospital, Bergen, Norway; Howard L. McLeod, Department of Medicine, Washington University Medicine School, St Louis, USA; Gerard Milano, Oncopharmacology Unit, Centre Antoine, Nice, France; Peter J. O'Dwyer, University of Pennsylvania Cancer Center, Philadelphia, USA; Curt Peterson, Department of Clinical Pharmacology, University Hospital of Linkoping, Sweden; Jacques Robert, Institute Bergonie, Comprehensive Cancer Center, Bordeaux-cedex, France; Hilde Rosing, Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands; Eric K. Rowinsky, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA; Jan H. M. Schellens, The Netherlands Cancer Institute, Amsterdam, The Netherlands; James P. Stevenson, University of Pennsylvania Cancer Center, Philadelphia, USA; Timothy W. Synold, Department of Medical Oncology, City of Hope National Medical Center, Duarte, USA; Lucia Vigano, Division of Medical Oncology A, Instituto Nazionale Tumori, Milan, Italy.
